High-Sensitivity Troponin I and Coronary Computed Tomography in Symptomatic Outpatients With Suspected CAD: Insights From the PROMISE Trial.


Journal

JACC. Cardiovascular imaging
ISSN: 1876-7591
Titre abrégé: JACC Cardiovasc Imaging
Pays: United States
ID NLM: 101467978

Informations de publication

Date de publication:
06 2019
Historique:
received: 08 12 2017
revised: 16 01 2018
accepted: 18 01 2018
pubmed: 20 3 2018
medline: 19 3 2020
entrez: 19 3 2018
Statut: ppublish

Résumé

The goal of this study was to examine associations between concentrations of high-sensitivity troponin I (hsTnI) (measured by using a single-molecule counting method) and obstructive coronary artery disease (CAD) in 1,844 stable, symptomatic outpatients with suspected CAD randomized to undergo coronary computed tomography angiography (CTA) in the PROMISE (Prospective Multicenter Imaging Study for Evaluation of Chest Pain) trial. Elevated concentrations of hsTnI are associated with CAD in patients with myocardial infarction. The meaning of hsTnI concentrations in stable symptomatic outpatients is not well understood. Clinical characteristics and CTA results (including coronary artery calcium [CAC] scores) were expressed across hsTnI quartiles. Determinants of hsTnI concentration were identified. Multivariable logistic regression identified independent predictors of obstructive CAD The median hsTnI concentration was 1.5 ng/l; nearly all (98.5%) subjects had measurable hsTnI, and 6.1% had concentrations ≥99th percentile concentration for this assay (6 ng/l). Higher CAC scores, as well as more prevalent and diffuse CAD, was seen in upper hsTnI quartiles (all p < 0.001). Independent predictors of hsTnI concentrations included age, sex, and CAC score (all p < 0.05). After adjusting for demographic and clinical characteristics, log-transformed hsTnI concentrations were associated with obstructive CAD In stable symptomatic outpatients undergoing nonemergent coronary CTA for the diagnosis of suspected CAD, higher concentrations of hsTnI were associated with increasing presence and severity of coronary atherosclerosis. (Prospective Multicenter Imaging Study for Evaluation of Chest Pain [PROMISE]; NCT01174550).

Sections du résumé

OBJECTIVES
The goal of this study was to examine associations between concentrations of high-sensitivity troponin I (hsTnI) (measured by using a single-molecule counting method) and obstructive coronary artery disease (CAD) in 1,844 stable, symptomatic outpatients with suspected CAD randomized to undergo coronary computed tomography angiography (CTA) in the PROMISE (Prospective Multicenter Imaging Study for Evaluation of Chest Pain) trial.
BACKGROUND
Elevated concentrations of hsTnI are associated with CAD in patients with myocardial infarction. The meaning of hsTnI concentrations in stable symptomatic outpatients is not well understood.
METHODS
Clinical characteristics and CTA results (including coronary artery calcium [CAC] scores) were expressed across hsTnI quartiles. Determinants of hsTnI concentration were identified. Multivariable logistic regression identified independent predictors of obstructive CAD
RESULTS
The median hsTnI concentration was 1.5 ng/l; nearly all (98.5%) subjects had measurable hsTnI, and 6.1% had concentrations ≥99th percentile concentration for this assay (6 ng/l). Higher CAC scores, as well as more prevalent and diffuse CAD, was seen in upper hsTnI quartiles (all p < 0.001). Independent predictors of hsTnI concentrations included age, sex, and CAC score (all p < 0.05). After adjusting for demographic and clinical characteristics, log-transformed hsTnI concentrations were associated with obstructive CAD
CONCLUSIONS
In stable symptomatic outpatients undergoing nonemergent coronary CTA for the diagnosis of suspected CAD, higher concentrations of hsTnI were associated with increasing presence and severity of coronary atherosclerosis. (Prospective Multicenter Imaging Study for Evaluation of Chest Pain [PROMISE]; NCT01174550).

Identifiants

pubmed: 29550314
pii: S1936-878X(18)30132-3
doi: 10.1016/j.jcmg.2018.01.021
pmc: PMC6129434
mid: NIHMS939909
pii:
doi:

Substances chimiques

Biomarkers 0
Troponin I 0

Banques de données

ClinicalTrials.gov
['NCT01174550']

Types de publication

Journal Article Multicenter Study Pragmatic Clinical Trial Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1047-1055

Subventions

Organisme : NCATS NIH HHS
ID : UL1 TR002548
Pays : United States
Organisme : NHLBI NIH HHS
ID : K24 HL113128
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL098237
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL098236
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL098305
Pays : United States

Commentaires et corrections

Type : CommentIn
Type : CommentIn
Type : ErratumIn

Informations de copyright

Copyright © 2019 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.

Références

Am Heart J. 2016 Mar;173:8-17
pubmed: 26920591
J Am Coll Cardiol. 2017 Mar 7;69(9):1147-1156
pubmed: 28254177
Circulation. 2017 Nov 21;136(21):1993-2005
pubmed: 28847895
Arterioscler Thromb Vasc Biol. 2016 Apr;36(4):757-64
pubmed: 26868212
Am Heart J. 2014 Jun;167(6):796-803.e1
pubmed: 24890527
Curr Cardiol Rep. 2016 May;18(5):40
pubmed: 26995403
J Am Coll Cardiol. 1990 Mar 15;15(4):827-32
pubmed: 2407762
Clin Chem. 2018 Feb;64(2):398-399
pubmed: 29046331
Stat Med. 2011 Jan 15;30(1):11-21
pubmed: 21204120
Circulation. 2010 Mar 16;121(10):1227-34
pubmed: 20194879
Am Heart J. 2015 Apr;169(4):572-8.e1
pubmed: 25819865
J Am Coll Cardiol. 2012 Oct 16;60(16):1581-98
pubmed: 22958960
JACC Cardiovasc Imaging. 2011 Aug;4(8):894-901
pubmed: 21835382
Circulation. 2017 Jun 13;135(24):2320-2332
pubmed: 28389572
JACC Cardiovasc Imaging. 2017 Oct;10(10 Pt A):1200-1203
pubmed: 28109924
N Engl J Med. 2015 Apr 2;372(14):1291-300
pubmed: 25773919

Auteurs

James L Januzzi (JL)

Cardiology Division, Massachusetts General Hospital, Boston, Massachusetts; Baim Institute for Clinical Research, Boston, Massachusetts. Electronic address: jjanuzzi@partners.org.

Sunil Suchindran (S)

Duke Center for Applied Genomics and Precision Medicine, Durham, North Carolina.

Adrian Coles (A)

Duke Clinical Research Institute, Duke University School of Medicine, Durham, North Carolina.

Maros Ferencik (M)

Oregon Health and Science University, Portland, Oregon.

Manesh R Patel (MR)

Duke Clinical Research Institute, Duke University School of Medicine, Durham, North Carolina.

Udo Hoffmann (U)

Department of Radiology, Massachusetts General Hospital, Boston, Massachusetts.

Geoffrey S Ginsburg (GS)

Duke Center for Applied Genomics and Precision Medicine, Durham, North Carolina; Department of Medicine, Duke University Medical School, Durham, North Carolina.

Pamela S Douglas (PS)

Duke Clinical Research Institute, Duke University School of Medicine, Durham, North Carolina; Department of Medicine, Duke University Medical School, Durham, North Carolina.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH